CN | EN
Development Strategy
Pipeline
Robust Pipeline with global rights and lead positions
Fields Project/Modality Target Indications Pre-clinical Phase Ⅰ Phase Ⅱ Phase Ⅲ Trial Regions Rights Regions Partner
Nephropathy SC0062
SM
ETA lgA
DKD
Oncology BC3195
ADC
CDH3 Soild tumor
Oncology BC3402
mAb
TIM-3 HCC
MDS/CMML
Oncology SC0245
SM
ATR Solid tumor
SCLC
Oncology SC0191
SM
WEE1 Solid tumor
Solid tumor
OC
Oncology BC3448
BsAb
CD3xEGFR Solid tumor
Oncology BC3425
mAb
4-1BB Solid tumor
Oncology ADC Undisclosed Solid tumor
Oncology Bs-Ab Undisclosed Solid tumor
Highly Differentiated
Science-Driven
Deeply understand the scientific mechanism, and improve the success rate of target selection
Clinically-Oriented
Strive to meet the unmet medical needs of the future and to foresee the trend the future clinical treatment scenarios
 
Long-term Commerical Value
Develop products with long-term commercial value
 
 
Focused Area
Chronic kidney disease(CKD)
Oncology
From anti-tumor to anti-tumor resistance